⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 13, 2024BMC CancerOpen Access

Association of low adherence to weekly cisplatin with outcomes in patients with head and neck squamous cell carcinoma: a retrospective cohort study

Jas Virk Jasmin Gill Fatemeh Fekrmandi Austin J. Iovoli Mark Farrugia Ayham Al-Afif Kimberly Wooten Vishal Gupta Ryan McSpadden Moni Abraham Kuriakose Michael R. Markiewicz Wesley L. Hicks Sung Jun Anurag K. Singh

View Full Paper

Ask AI

Bookmark

Share

Abstract

The National Comprehensive Cancer Network (NCCN) guideline recommends consideration of weekly cisplatin as an alternative option for patients with head and neck cancer undergoing definitive chemoradiation. However, in a recent phase III trial (ConCERT), 20% of patients treated with weekly cisplatin could not receive a total of 200 mg/m

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Virk et al. (2024) studied this question.

synapsesocial.com/papers/68e6066db6db64358759a41b https://doi.org/10.1186/s12885-024-12615-w

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of low adherence to weekly cisplatin with outcomes in patients with head and neck cancer treated with chemoradiation.2024
2Concurrent chemotherapy and external radiation therapy (ConCERT): phase 3 noninferiority randomized clinical trial of cisplatin weekly vs every 3 weeks in locally advanced squamous cell carcinoma of the head and neckRCT · 2026
3Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck CancerCohort Study · 2026
4Real-life data on the use of three-weekly versus weekly cisplatin concomitant with radiotherapy in the locoregional treatment of patients with head and neck squamous cell carcinomaMeta-Analysis · 2026
5Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck CancerEarly-Phase Clinical Trial · 2026 · 1 citations